- €9.49bn
- €9.62bn
- €1.89bn
Brief: Orion Raises Outlook For 2025
Brief: CHMP Recommends Third Indication For Darolutamide For Patients With Advanced Prostate Cancer
Brief: Orion, Glykos Announce Extension Of Research Collaboration, Licensing Agreement
Brief: Orion Signs Agreement With Shilpa Medicare
Brief: Orion And Criceto Announce License Agreement For Aporon
Orion gains on strong Q1 results, driven by sales of Nubeqa
Brief: Orion Q1 Sales Up At EUR 354.6 Million
Earnings Poll: Orion first quarter results due on April 23
Brief: Orion Concludes Statutory Negotiations In Turku
Brief: Court Of Appeal Fines Orion Board Member
Brief: Orion To Open New Centre In Cambridge, In 2025 To Support Global Growth Strategy, Considers Reorganizing Some Work In Turku
Brief: Orion And Aiforia Extend Collaboration To Preclinical Study Evaluations
Nubeqa strength boosts Orion shares
Orion gains on another outlook hike
Brief: Orion, Marinus Terminate Agreement For Ganaxolone In Europe
Brief: Orion, Abilita Therapeutics Announce Research Collaboration
Brief: Orion Oyj Says Financial Supervisory Authority Has Imposed Penalty Payment Of EUR 6,000 On Ari Lehtoranta, Member Of Board Of Directors Of Orion
Brief: Orion And Alligator Bioscience Amend Their Agreement Concerning Two Bispecific Antibodies
Brief: Orion Keeps 2024 Outlook